About: Viral vectors for malaria vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Viral vectors for malaria vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Viral vectors for malaria vaccine development
Creator	Zavala, Fidel Bruder, Joseph Clarke, David Dubovsky, Filip Li, Shengqiang Liljestrom, Peter Locke, Emily Ockenhouse, Christian Viret, Jean-Francois Naim, Hussein Hill, Adrian Monath, Thomas Doolan, Denise Havenga, Menzo Van Kampen, Kent Tang, De-chu
Source	PMC
abstract	A workshop on viral vectors for malaria vaccine development, organized by the PATH Malaria Vaccine Initiative, was held in Bethesda, MD on October 20, 2005. Recent advancements in viral-vectored malaria vaccine development and emerging vector technologies were presented and discussed. Classic viral vectors such as poxvirus, adenovirus and alphavirus vectors have been successfully used to deliver malaria antigens. Some of the vaccine candidates have demonstrated their potential in inducing malaria-specific immunity in animal models and human trials. In addition, emerging viral-vector technologies, such as measles virus (MV), vesicular stomatitis virus (VSV) and yellow fever (YF) virus, may also be useful for malaria vaccine development. Studies in animal models suggest that each viral vector is unique in its ability to induce humoral and/or cellular immune responses. Those studies have also revealed that optimization of Plasmodium genes for mammalian expression is an important aspect of vaccine design. Codon-optimization, surface-trafficking, de-glycosylation and removal of toxic domains can lead to improved immunogenicity. Understanding the vector's ability to induce an immune response and the expression of malaria antigens in mammalian cells will be critical in designing the next generation of viral-vectored malaria vaccines.
has issue date	2007-03-30(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2006.07.035
bibo:pmid	16914237
has license	no-cc
schema:url	https://doi.org/10.1016/j.vaccine.2006.07.035
resource representing a document's title	Viral vectors for malaria vaccine development
has PubMed Central identifier	PMC7131149
has PubMed identifier	16914237
schema:publication	Vaccine
resource representing a document's body	covid:PMC7131149#body_text
is schema:about of	named entity 'Viral vectors' named entity 'antigens' named entity 'flavivirus' named entity 'immunization' named entity 'env' named entity 'replicons' named entity 'CD8+ T-cells' named entity 'gene' named entity 'HIV' named entity 'HIV' named entity 'cytoplasmic' named entity 'immunization' named entity 'protein expression' named entity 'CMI' named entity 'immunogenicity' named entity 'cGMP' named entity 'immunogenic' named entity 'parasites' named entity 'synergies' named entity 'Ad5' named entity 'immunization' named entity 'parasite' named entity 'recombinant proteins' named entity 'FACS' named entity 'antigens' named entity 'parasite' named entity 'Dengue' named entity 'adenovirus' named entity 'correlation' named entity 'immunogenicity' named entity 'vesicular' named entity 'immune responses' named entity 'adjuvant' named entity 'immune response' named entity 'conformers' named entity 'transgenic mouse model' named entity 'Viral vectors' named entity 'O-glycosylation' named entity 'protozoan' named entity 'vector' named entity 'T-cell' named entity 'alphavirus' named entity 'CMI' named entity 'CSP' named entity 'gene' named entity 'Immune responses' named entity 'RNA virus' named entity 'flu-like illness' named entity 'field trial' named entity 'glycosylphosphatidylinositol (GPI) anchor' named entity 'electroporation' named entity 'mammalian cells' named entity 'Ad5' named entity 'D. Clarke' named entity 'P. berghei' named entity 'vector' named entity 'vaccine' named entity 'immunogenic' named entity 'adenovirus' named entity 'immunogenic' named entity 'malaria' named entity 'vaccine' named entity 'vaccine' named entity 'SFV' named entity 'immunogenic' named entity 'gene expression' named entity 'signal sequence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software